Eejung Kim

This study shows that KRASG12C inhibitors alter the surface proteome of lung cancer cells, revealing FOLR1 as a new target when combined with an antibody drug conjugate.

This study uses deep mutational scanning to analyze KRAS variants, identifying gain- and loss-of-function mechanisms and their impact on oncogenic activity.

This study identifies how mutant KRAS reprograms the noncoding transcriptome, upregulating repetitive noncoding RNAs and inducing IFN-stimulated genes through epigenetic and RNA-based mechanisms.